Neurol. praxi. 2025;26(2):135-141 | DOI: 10.36290/neu.2025.002

Prodromal Parkinson's disease - making the diagnosis in the premotor stage

doc. MUDr. Petr Dušek, Ph.D.
Neurologická klinika a Centrum klinických neurověd, 1. lékařská fakulta, Univerzita Karlova a Všeobecná fakultní nemocnice v Praze

Prodromal Parkinson's disease (PD) manifests with a wide range of clinical symptoms and biological markers, including autonomic nervous system dysfunction, neuropsychiatric symptoms, sleep disorders, hypomimia, and dysarthria. Ultrasound and scintigraphic examinations, genetic variants (e.g., GBA1, LRRK2), and detection of pathological α-synuclein provide valuable diagnostic tools for early identification of at-risk individuals. Despite advancements in diagnostics, effective treatment for the prodromal stage is unavailable, raising ethical questions regarding prognosis communication and patient support. Future research is expected to focus on early neuroprotective interventions and biomarker validation.

Keywords: Parkinson disease, REM sleep behavioral disorder, hyposmia, genetics, DAT-SPECT.

Received: January 7, 2025; Revised: January 7, 2025; Accepted: January 15, 2025; Published: May 5, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dušek P. Prodromal Parkinson's disease - making the diagnosis in the premotor stage. Neurol. praxi. 2025;26(2):135-141. doi: 10.36290/neu.2025.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 5.5.2026

    References

    1. Arnaldi D, Chincarini A, Hu MT, et al. Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain. 2021;144(1):278-287. https://doi.org/10.1093/brain/awaa365. Go to original source... Go to PubMed...
    2. Behnke S, Runkel A, Kassar HA, et al. Long-term course of substantia nigra hyperechogenicity in Parkinson's disease. Mov Disord. 2013;28(4):455-459. https://doi.org/10.1002/mds.25193. Go to original source... Go to PubMed...
    3. Berg D, Behnke S, Seppi K, et al. Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord. 2013;28(2):216-219. https://doi.org/10.1002/mds.25192. Go to original source... Go to PubMed...
    4. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015;30(12):1600-1611. https://doi.org/10.1002/mds.26431. Go to original source... Go to PubMed...
    5. Boesveldt S, Postma EM, Boak D, et al. Anosmia - A Clinical Review. Chem Senses. 2017;42(7):513-523. https://doi.org/10.1093/chemse/bjx025. Go to original source... Go to PubMed...
    6. Dauvilliers Y, Schenck CH, Postuma RB, et al. REM sleep behaviour disorder. Nat Rev Dis Primers. 2018;4(1):19. https://doi.org/10.1038/s41572-018-0016-5. Go to original source... Go to PubMed...
    7. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav. 1984;32(3):489-502. https://doi.org/10.1016/0031-9384(84)90269-5. Go to original source... Go to PubMed...
    8. Dušek P, Bezdíček O, Brožová H, et al. Clinical characteristics of newly dia gnosed Parkinson's disease patients included in the longitudinal BIO-PD study. Ceska a Slovenska Neurologie a Neurochirurgie. 2020;83/116(6):633-639. https://doi.org/10.48095/cccsnn2020633. Go to original source...
    9. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114( Pt 5):2283-2301. https://doi.org/10.1093/brain/114.5.2283. Go to original source... Go to PubMed...
    10. Fereshtehnejad SM, Yao C, Pelletier A, et al. Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study. Brain. 2019;142(7):2051-2067. https://doi.org/10.1093/brain/awz111. Go to original source... Go to PubMed...
    11. Gibbons CH, Levine T, Adler C, et al. Skin Biopsy Detection of Phosphorylated alpha-Synuclein in Patients With Synucleinopathies. JAMA. 2024;331(15):1298-1306. https://doi.org/10.1001/jama.2024.0792. Go to original source... Go to PubMed...
    12. Heinzel S, Berg D, Gasser T, et al. Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2019;34(10):1464-1470. https://doi.org/10.1002/mds.27802. Go to original source... Go to PubMed...
    13. Hoglinger GU, Adler CH, Berg D, et al. A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23(2):191-204. https://doi.org/10.1016/S1474-4422(23)00404-0. Go to original source... Go to PubMed...
    14. Hummel T, Sekinger B, Wolf SR, et al. 'Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses. 1997;22(1):39-52. https://doi.org/10.1093/chemse/22.1.39. Go to original source... Go to PubMed...
    15. Jacobs BM, Belete D, Bestwick J, et al. Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank. J Neurol Neurosurg Psychiatry. 2020;91(10):1046-1054. https://doi.org/10.1136/jnnp-2020-323646. Go to original source... Go to PubMed...
    16. Jennings D, Siderowf A, Stern M, et al. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology. 2014;83(19):1739-1746. https://doi.org/10.1212/WNL.0000000000000960. Go to original source... Go to PubMed...
    17. Jia F, Fellner A, Kumar KR. Monogenic Parkinson's Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing. Genes (Basel). 2022;13(3). https://doi.org/10.3390/genes13030471. Go to original source... Go to PubMed...
    18. Kalra DK, Raina A, Sohal S. Neurogenic Orthostatic Hypotension: State of the Art and Therapeutic Strategies. Clin Med Insights Cardiol. 2020;14:1179546820953415. https://doi.org/10.1177/1179546820953415. Go to original source... Go to PubMed...
    19. Kim JJ, Vitale D, Otani DV, et al. Multi-ancestry genome-wide association meta-analysis of Parkinson's disease. Nat Genet. 2024;56(1):27-36. https://doi.org/10.1038/s41588-023-01584-8. Go to original source... Go to PubMed...
    20. Koeglsperger T, Rumpf SL, Schliesser P, et al. Neuropathology of incidental Lewy body & prodromal Parkinson's disease. Mol Neurodegener. 2023;18(1):32. https://doi.org/10.1186/s13024-023-00622-7. Go to original source... Go to PubMed...
    21. Kuang Y, Mao H, Huang X, et al. Alpha-Synuclein seeding amplification assays for diagnosing synucleinopathies: an innovative tool in clinical implementation. Transl Neurodegener. 2024;13(1):56. https://doi.org/10.1186/s40035-024-00449-2. Go to original source... Go to PubMed...
    22. Lee WJ, Baek SH, Im HJ, et al. REM Sleep Behavior Disorder and Its Possible Prodromes in General Population: Prevalence, Polysomnography Findings, and Associated Factors. Neurology. 2023;101(23):e2364-e2375. https://doi.org/10.1212/WNL.0000000000207947. Go to original source... Go to PubMed...
    23. Lyu Z, Zheng S, Zhang X, et al. Olfactory impairment as an early marker of Parkinson's disease in REM sleep behaviour disorder: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2021;92(3):271-281. https://doi.org/10.1136/jnnp-2020-325361. Go to original source... Go to PubMed...
    24. Maskova J, Skoloudik D, Stofanikova P, et al. Comparative study of the substantia nigra echogenicity and (123)I-Ioflupane SPECT in patients with synucleinopathies with and without REM sleep behavior disorder. Sleep Med. 2020;70:116-123. https://doi.org/10.1016/j.sleep.2020.02.012. Go to original source... Go to PubMed...
    25. Norcliffe-Kaufmann L, Kaufmann H, Palma JA, et al. Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies. Ann Neurol. 2018;83(3):522-531. https://doi.org/10.1002/ana.25170. Go to original source... Go to PubMed...
    26. O'Hara DM, Kalia SK, Kalia LV. Methods for detecting toxic alpha-synuclein species as a biomarker for Parkinson's disease. Crit Rev Clin Lab Sci. 2020;57(5)291-307. https://doi.org/10.1080/10408363.2019.1711359. Go to original source... Go to PubMed...
    27. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. https://doi.org/10.1038/nrdp.2017.13 Go to original source... Go to PubMed...
    28. Postuma RB, Berg D. Prodromal Parkinson's Disease: The Decade Past, the Decade to Come. Mov Disord. 2019;34(5):665-675. https://doi.org/10.1002/mds.27670. Go to original source... Go to PubMed...
    29. Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019;142(3):744-759. https://doi.org/10.1093/brain/awz030. Go to original source... Go to PubMed...
    30. Rusz J, Hlavnicka J, Novotny M, et al. Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease. Ann Neurol. 2021;90(1):62-75. https://doi.org/10.1002/ana.26085. Go to original source... Go to PubMed...
    31. Seibler P, Streubel-Gallasch L, Klein C. Combining Biomarkers with Genetics In Prodromal/Earliest Phase Parkinson's Disease. J Parkinsons Dis. 2024;14(s2):S345-S351. https://doi.org/10.3233/JPD-240155. Go to original source... Go to PubMed...
    32. Schaeffer E, Yilmaz R, St Louis EK, et al. Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson's Disease: A Narrative Review. J Parkinsons Dis. 2024;14(s2):S307-S319. https://doi.org/10.3233/JPD-230428. Go to original source... Go to PubMed...
    33. Schalkamp AK, Peall KJ, Harrison NA, et al. Wearable movement-tracking data identify Parkinson's disease years before clinical diagnosis. Nat Med. 2023;29(8):2048-2056. https://doi.org/10.1038/s41591-023-02440-2. Go to original source... Go to PubMed...
    34. Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407-417. https://doi.org/10.1016/S1474-4422(23)00109-6. Go to original source... Go to PubMed...
    35. Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178-190. https://doi.org/10.1016/S1474-4422(23)00405-2. Go to original source... Go to PubMed...
    36. Singer W, Berini SE, Sandroni P, et al. Pure autonomic failure: Predictors of conversion to clinical CNS involvement. Neurology. 2017;88(12):1129-1136. https://doi.org/10.1212/WNL.0000000000003737. Go to original source... Go to PubMed...
    37. Sixel-Doring F, Muntean ML, Petersone D, et al. The Increasing Prevalence of REM Sleep Behavior Disorder with Parkinson's Disease Progression: A Polysomnography-Supported Study. Mov Disord Clin Pract. 2023;10(12):1769-1776. https://doi.org/10.1002/mdc3.13908. Go to original source... Go to PubMed...
    38. Yoo HS, Chung SJ, Lee YH, et al. Olfactory anosognosia is a predictor of cognitive decline and dementia conversion in Parkinson's disease. J Neurol. 2019;266(7):1601-1610. https://doi.org/10.1007/s00415-019-09297-x. Go to original source... Go to PubMed...
    39. Zitser J, During EH, Chiaro G, et al. Autonomic impairment as a potential biomarker in idiopathic REM-sleep-behavior disorder. Auton Neurosci. 2019;220:102553. https://doi.org/10.1016/j.autneu.2019.05.005 . Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.